SCHEMBL792173

SCHEMBL792173

Cc1ccc2c(C3CCCCC3)c3n(c2c1)CCN(CC(=O)OC(C)(C)C)c1ccccc1-3

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCA P17252 1/20 0.37
MMP12 P39900 1/20 0.37
CCKBR P32239 4/20 0.36
SCN9A Q15858 2/20 0.36
SCN10A Q9Y5Y9 1/20 0.36
NR1I2 O75469 1/20 0.33
HTR4 Q13639 1/20 0.33
NPC1 O15118 2/20 0.33
MAPT P10636 2/20 0.33
RAB9A P51151 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
HTT P42858 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
KDM4E B2RXH2 1/20 0.32
MEN1 O00255 1/20 0.32
ALDH1A1 P00352 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14572855 0.88 PRKCA (0.40) PRKCAMMP12SCN9ASCN10ANR1I2
SCHEMBL792424 0.87 PRKCA (0.41) PRKCAMMP12CCKBRSCN9ANR1I2
SCHEMBL12427556 0.85 KDM1A (0.37) PRKCAMMP12SCN9ANR1I2MAPT
SCHEMBL792654 0.85 GPR119 (0.40) KDM4E
SCHEMBL792560 0.82 CHRM2 (0.39) PRKCAMMP12CCKBRSCN9ANR1I2
SCHEMBL792821 0.78 MAPK1 (0.40) SCN9ANR1I2NPSR1MAPK1
SCHEMBL792836 0.77 PRKCA (0.33) PRKCAMMP12NPC1MAPTRAB9A
SCHEMBL14572856 0.77 PRKCA (0.44) PRKCAMMP12SCN9ANR1I2CYP3A4
SCHEMBL792846 0.77 PRKCA (0.33) PRKCAMMP12NPC1MAPTRAB9A
SCHEMBL792562 0.76 PRKCA (0.33) PRKCAMMP12SCN9ANR1I2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120070409-A1 TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR JAPAN TOBACCO INC. (JP) 2012-03-22 US disclosed
US-7977331-B1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2011-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120070409-A1 TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR POLI, TERT, ZC3HAV1 PRKCA 2404/4885MMP12 1013/4885CCKBR 2746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.